Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
610 · 2 trials · 1 indication
Annualized rate of severe exacerbation events during the 52-week placebo-controlled treatment period
FEV1 is defined as the volume of air expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry.
| Arm | Type | Description |
|---|---|---|
| 610 group | EXPERIMENTAL | Subjects will receive 610 for 52 weeks. |
| placebo group | PLACEBO_COMPARATOR | Subjects will receive placebo for 52 weeks. |
| Group A | EXPERIMENTAL | Subjects will receive 610 for 52 weeks. |
| Group B | EXPERIMENTAL | Subjects will receive 610 for 52 weeks. |
| Name | Type | Description |
|---|---|---|
| 610 | DRUG | 610 subcutaneously injection. |
| Placebo | DRUG | Placebo subcutaneously injection. |
Inclusion Criteria: 1. Able to give written informed consent prior to participation in the study. 2. Male or female adults ages 18 to 75 years old when signing the informed consent. 3. Documented diagnosis of asthma for at least one year prior to screening. 4. History of physician-diagnosed asthma ...